Payne JN - Search Results

1

Novel Synthesis of Kanamycin Conjugated Gold Nanoparticles with Potent Antibacterial Activity.

Payne JN, Waghwani HK, Connor MG, Hamilton W, Tockstein S, Moolani H, Chavda F, Badwaik V, Lawrenz MB, Dakshinamurthy R. Payne JN, et al. Front Microbiol. 2016 May 2;7:607. doi: 10.3389/fmicb.2016.00607. eCollection 2016. Front Microbiol. 2016. PMID: 27330535 Free PMC article.

2

Development of dihydrochalcone-functionalized gold nanoparticles for augmented antineoplastic activity.

Payne JN, Badwaik VD, Waghwani HK, Moolani HV, Tockstein S, Thompson DH, Dakshinamurthy R. Payne JN, et al. Int J Nanomedicine. 2018 Mar 28;13:1917-1926. doi: 10.2147/IJN.S143506. eCollection 2018. Int J Nanomedicine. 2018. PMID: 29636609 Free PMC article.

3

Nanotechnology's Impact on Medicinal Chemistry.

Hamilton W, Modi T, Waghwani HK, Tockstein S, Payne J, Filani O, Badwaik V, Shah M, Webb C, Lawrenz MB, Dakshinamurthy R. Hamilton W, et al. Mini Rev Med Chem. 2015 May 11. Online ahead of print. Mini Rev Med Chem. 2015. PMID: 25963566

4

Management of Acute Sickle Cell Disease Pain.

Payne JN, Gee BE. Payne JN, et al. Pediatr Rev. 2024 Jan 1;45(1):26-38. doi: 10.1542/pir.2022-005631. Pediatr Rev. 2024. PMID: 38161155

5

Enzyme Sensing Using 2-Mercaptopyridine-Carbonitrile Reporters and Surface-Enhanced Raman Scattering.

Morsby JJ, Thimes RL, Olson JE, McGarraugh HH, Payne JN, Camden JP, Smith BD. Morsby JJ, et al. Among authors: payne jn. ACS Omega. 2022 Feb 9;7(7):6419-6426. doi: 10.1021/acsomega.2c00139. eCollection 2022 Feb 22. ACS Omega. 2022. PMID: 35224403 Free PMC article.

6

Inequalities in access to knee joint replacements for people in need.

Yong PF, Milner PC, Payne JN, Lewis PA, Jennison C. Yong PF, et al. Among authors: payne jn. Ann Rheum Dis. 2004 Nov;63(11):1483-9. doi: 10.1136/ard.2003.013938. Ann Rheum Dis. 2004. PMID: 15479899 Free PMC article.

7

Inequalities in accessing hip joint replacement for people in need.

Milner PC, Payne JN, Stanfield RC, Lewis PA, Jennison C, Saul C. Milner PC, et al. Among authors: payne jn. Eur J Public Health. 2004 Mar;14(1):58-62. doi: 10.1093/eurpub/14.1.58. Eur J Public Health. 2004. PMID: 15080393

8

The SF36 as an outcome measure of services for end stage renal failure.

Wight JP, Edwards L, Brazier J, Walters S, Payne JN, Brown CB. Wight JP, et al. Among authors: payne jn. Qual Health Care. 1998 Dec;7(4):209-21. doi: 10.1136/qshc.7.4.209. Qual Health Care. 1998. PMID: 10339023 Free PMC article.

9

Lipid-lowering for prevention of coronary heart disease: what policy now?

Ul Haq I, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN. Ul Haq I, et al. Among authors: payne jn. Clin Sci (Lond). 1996 Oct;91(4):399-413. doi: 10.1042/cs0910399. Clin Sci (Lond). 1996. PMID: 8983865

10

Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table.

Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Ramsay LE, et al. Among authors: payne jn. Lancet. 1996 Aug 10;348(9024):387-8. doi: 10.1016/s0140-6736(96)05516-x. Lancet. 1996. PMID: 8709740 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters